<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075554</url>
  </required_header>
  <id_info>
    <org_study_id>RGC10-009-001-PL_H_2</org_study_id>
    <nct_id>NCT02075554</nct_id>
  </id_info>
  <brief_title>Study of an Expandable Interbody Device for the Lumbar Spine</brief_title>
  <acronym>CALIBER</acronym>
  <official_title>Efficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mt. Sinai Medical Center, Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carolina Neurosurgery &amp; Spine Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Globus Medical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and efficacy of CALIBER&#xD;
      expandable spacer for the treatment of degenerative disc disease. Radiographic outcomes,&#xD;
      intra-operative parameters, clinical outcomes, and patient satisfaction will be obtained from&#xD;
      patients in this 2 year follow-up clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed-up at 3weeks, 6 weeks, 3 months, 6 months, 12 and 24 months with&#xD;
      X-rays and questionnaires to determine their satisfaction, healing, fusion and return to work&#xD;
      status&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Lumbar interbody cages</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion and Disc Height Maintenance</measure>
    <time_frame>24 months</time_frame>
    <description>Inter-vertebral disc height in millimetres at 24 month follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fusion Assessment</measure>
    <time_frame>24 months</time_frame>
    <description>An assessment of the fusion status of surgically treated spinal levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Self Assessment</measure>
    <time_frame>Upto 24 mo</time_frame>
    <description>Oswestry Disability Index. A 10 item questionnaire with responses scored 0 to 5 and then presented as a percentage score from 0 to 100, with higher scores denoting more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Back Pain</measure>
    <time_frame>24 months</time_frame>
    <description>A visual scale from 0 to 100 in which the patient responds with their pain level by marking on the line, higher as more severe pain.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>CALIBER</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CALIBER</intervention_name>
    <description>Expandable interbody spacer</description>
    <arm_group_label>CALIBER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DDD at 1 or 2 levels between L2 and S1&#xD;
&#xD;
          -  Between 18 and 80 years of age&#xD;
&#xD;
          -  Unresponsiveness to documented non-surgical treatment modalities for a minimum of six&#xD;
             months&#xD;
&#xD;
          -  Ability to provide a signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Trauma at level(s) to be fused&#xD;
&#xD;
          -  Previous documentation of osteopenia, osteoporosis, or osteomalacia to a degree that&#xD;
             spinal instrumentation would be contraindicated&#xD;
&#xD;
          -  Immunosuppressive disorder&#xD;
&#xD;
          -  History of substance abuse&#xD;
&#xD;
          -  Any known allergy to a metal alloy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Florida Spine Institute at Mt Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina NeuroSurgery and Spine Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>February 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The protocol was approved to enroll 60 patients but only 58 patients were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CALIBER</title>
          <description>1 or 2 levels of Degenerative Disc Disease between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes only those patients who completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>CALIBER</title>
          <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="32" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fusion and Disc Height Maintenance</title>
        <description>Inter-vertebral disc height in millimetres at 24 month follow up.</description>
        <time_frame>24 months</time_frame>
        <population>Not all patients had x ray images to measure at 24 month follow up. A total of 33 surgical levels were measured from 29 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>CALIBER</title>
            <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
          </group>
        </group_list>
        <measure>
          <title>Fusion and Disc Height Maintenance</title>
          <description>Inter-vertebral disc height in millimetres at 24 month follow up.</description>
          <population>Not all patients had x ray images to measure at 24 month follow up. A total of 33 surgical levels were measured from 29 patients.</population>
          <units>millimetres</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Surgical Levels</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surgical Levels</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.60" lower_limit="8.62" upper_limit="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fusion Assessment</title>
        <description>An assessment of the fusion status of surgically treated spinal levels.</description>
        <time_frame>24 months</time_frame>
        <population>Only 29 patients were available for fusion assessment at 24 months, for a total of 33 surgical levels.</population>
        <group_list>
          <group group_id="O1">
            <title>CALIBER</title>
            <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
          </group>
        </group_list>
        <measure>
          <title>Fusion Assessment</title>
          <description>An assessment of the fusion status of surgically treated spinal levels.</description>
          <population>Only 29 patients were available for fusion assessment at 24 months, for a total of 33 surgical levels.</population>
          <units>Surgical Levels</units>
          <param>Count of Units</param>
          <units_analyzed>Surgical Levels</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surgical Levels</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self Assessment</title>
        <description>Oswestry Disability Index. A 10 item questionnaire with responses scored 0 to 5 and then presented as a percentage score from 0 to 100, with higher scores denoting more disability.</description>
        <time_frame>Upto 24 mo</time_frame>
        <population>Not all patients completed the Oswestry Disability Index questionnaire at 24 month follow up, leaving 38 responses.</population>
        <group_list>
          <group group_id="O1">
            <title>CALIBER</title>
            <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Self Assessment</title>
          <description>Oswestry Disability Index. A 10 item questionnaire with responses scored 0 to 5 and then presented as a percentage score from 0 to 100, with higher scores denoting more disability.</description>
          <population>Not all patients completed the Oswestry Disability Index questionnaire at 24 month follow up, leaving 38 responses.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.79" lower_limit="0" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale for Back Pain</title>
        <description>A visual scale from 0 to 100 in which the patient responds with their pain level by marking on the line, higher as more severe pain.</description>
        <time_frame>24 months</time_frame>
        <population>38 patients completed the question at 24 month follow up</population>
        <group_list>
          <group group_id="O1">
            <title>CALIBER</title>
            <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale for Back Pain</title>
          <description>A visual scale from 0 to 100 in which the patient responds with their pain level by marking on the line, higher as more severe pain.</description>
          <population>38 patients completed the question at 24 month follow up</population>
          <units>score on a scale out of 100</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.71" lower_limit="0" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were assessed for adverse events by their physician over 24 months postoperative time period at each follow up point (Intraoperatively, 6 weeks, 3 months, 6 months, 12 months and 24 months postoperatively).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CALIBER</title>
          <description>1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion&#xD;
CALIBER: Expandable interbody spacer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI may release for publication with Sponsor's prior approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brandon Bucklen</name_or_title>
      <organization>Globus Medical Inc.</organization>
      <phone>610-930-1800 ext 2517</phone>
      <email>bbucklen@globusmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

